Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional) (PAR-22-089)
Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging
Due Date: Multiple due dates; see announcement.